Related Experiment Video
Updated: May 24, 2026

HUVEC Tube-formation Assay to Evaluate the Impact of Natural Products on Angiogenesis
Published on: June 24, 2019
Functional role of wogonin in anti-angiogenesis
Chiu-Mei Lin1, Yen-Hsu Chen, Jiann-Ruey Ong
1Department of Emergency Medicine, Shin Kong Wu Ho-Su Memorial Hospital, No. 95 Wen-Cheng Road, Shin Lin, Taipei, Taiwan.
Abstract:
Constitutive activation of the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway occurs commonly in cancer cells and endothelial cells, and contributes to angiogenesis. Wogonin is a compound with many biologically relevant properties. We previously reported that wogonin blocked IL-6-induced angiogenesis through suppression of VEGF expression, an important regulator of angiogenesis. However, the pathway involved in the suppressive effect of wogonin on IL-6-induced VEGF has not been completely clarified. This study aimed to investigate the molecular mechanisms participating in the suppression of wogonin on IL-6-induced VEGF in vitro, focusing on IL-6R/JAK1/STAT3/VEGF pathway. Both STAT3 siRNA and wogonin treatment resulted in an abolition of the expression of VEGF. Moreover, our data revealed that wogonin treatment after STAT3 knock-down did not further suppress VEGF expression. The addition of IL-6R siRNA or wogonin resulted in a decrease in the expression level of the phosphorylated JAK1 protein. Furthermore, wogonin significantly decreased the amount of phosphorylated STAT3. Finally, by EMSA, wogonin suppressed IL-6-induced STAT3 binding activity in a concentration-dependent manner. Taken together, our results show that wogonin suppresses IL-6-induced VEGF by modulating the IL-6R/JAK1/STAT3 signaling pathway. Based on this study, we suggest that wogonin may provide a new potential therapeutic option for treatment of IL-6-related pathological angiogenesis.
Insights
Wogonin suppresses IL-6-induced vascular endothelial growth factor (VEGF) by targeting the IL-6 receptor/Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway, offering potential for treating pathological angiogenesis.
Area of Science:
- Molecular Biology
- Cancer Research
- Pharmacology
Background:
- Constitutive activation of the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is common in cancer and promotes angiogenesis.
- Wogonin is a compound with known biological activities, previously shown to inhibit IL-6-induced angiogenesis by suppressing VEGF expression.
Purpose of the Study:
- To elucidate the molecular mechanisms by which wogonin suppresses IL-6-induced VEGF expression.
- To investigate the role of the IL-6 receptor (IL-6R)/JAK1/STAT3/VEGF pathway in wogonin's anti-angiogenic effects.
Main Methods:
- In vitro experiments utilizing siRNA for STAT3 and IL-6R.
- Western blotting to assess protein expression and phosphorylation levels (JAK1, STAT3).
- Electrophoretic Mobility Shift Assay (EMSA) to evaluate STAT3 binding activity.
Main Results:
- Both STAT3 siRNA and wogonin treatment abolished VEGF expression.
- Wogonin did not further suppress VEGF after STAT3 knockdown.
- Wogonin and IL-6R siRNA decreased phosphorylated JAK1; wogonin reduced phosphorylated STAT3.
- Wogonin inhibited IL-6-induced STAT3 binding activity in a concentration-dependent manner.
Conclusions:
- Wogonin suppresses IL-6-induced VEGF expression by modulating the IL-6R/JAK1/STAT3 signaling pathway.
- Wogonin shows potential as a therapeutic agent for treating pathological angiogenesis associated with IL-6 signaling.
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
Mechanism of Angiogenesis
Non-Canonical Wnt Signaling Pathways
Non-Canonical Wnt Signaling Pathways
Canonical Wnt Signaling Pathway
Canonical Wnt Signaling Pathway

